Congress mandates free breast cancer screening for high-risk women across all insurers

What it does

This bill requires health insurers, Medicare, Medicaid, TRICARE, and the VA to cover breast cancer screening and diagnostic imaging with zero cost-sharing for individuals at elevated risk—including those with dense breast tissue, family history, or other risk factors—starting January 1, 2026. The bill covers multiple imaging technologies (mammograms, ultrasound, MRI, etc.) at frequencies recommended by the National Comprehensive Cancer Network, removing financial barriers to early detection for high-risk populations.

Why we flagged it

The bill's core function is to mandate zero-cost-sharing coverage for breast cancer screening across all major insurance systems for high-risk individuals. It is a public-health measure, not a tax provision, subsidy, or deregulation.

What the text implies

• Imaging providers (radiology centers, hospitals) will see increased volume of screening procedures, potentially raising demand for imaging equipment and technicians.
• Insurers will absorb costs of expanded screening coverage; private insurers may offset costs through premium adjustments or reduced coverage elsewhere.
• The bill relies on clinical guidelines (NCCN, ACR) to define 'increased risk' and appropriate frequency, delegating eligibility determination to providers and external standard-setters rather than statutory definition.
• Veterans and TRICARE beneficiaries gain coverage without enrollment requirements, potentially expanding access beyond current VA/TRICARE populations.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill removes financial barriers to breast cancer screening for high-risk individuals across all major insurance systems (private, Medicare, Medicaid, TRICARE, VA), enabling earlier detection and potentially better health outcomes. The cost is borne by insurers and public programs, not individuals, and the public-health benefit of early detection outweighs the administrative burden on payers.

Who stands to gain

• radiology and imaging centers
• hospitals and diagnostic imaging providers
• breast imaging equipment manufacturers

Named in the bill

National Comprehensive Cancer Network (NCCN), American College of Radiology (ACR), Centers for Medicare & Medicaid Services (CMS), Department of Veterans Affairs (VA), Department of Defense (TRICARE), Medicaid state programs, Private health insurers, ERISA group health plans

Where it stands

76 cosponsors: 66 Democrats, 10 Republicans.

• Nov 20, 2025 — Introduced · Congress.gov: “Introduced in House”
• Nov 20, 2025 — Referred to House Committee on Veterans' Affairs and House Committee on Armed Services · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

2 lobbying clients named this bill on 3 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $790,000 in lobbying spend. A filing names 16 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 41% of bills with at least one filing.

Rosa DeLauro, the sponsor, reported $624,463 in PAC receipts in the 2026 cycle.

• GE Healthcare Technologies Inc. — $730,000 on 2 filings
• Hadassah, the Women's Zionist Organization of America, Inc. — $60,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.